Insight Molecular Diagnostics Inc.
US ˙ NasdaqCM ˙ US68235C2061

Introduction

This page provides a comprehensive analysis of the known insider trading history of Michael D West. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Michael D West has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:AGE / AgeX Therapeutics, Inc. Chief Executive Officer 41,982
US:LCTX / Lineage Cell Therapeutics, Inc. Co-Chief Executive Officer, Director 0
US:OCX / OncoCyte Corporation Director 60,000
VP of Technology Integration, Director 3,846
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Michael D West. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases IMDX / Insight Molecular Diagnostics Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in IMDX / Insight Molecular Diagnostics Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IMDX / Insight Molecular Diagnostics Inc. Insider Trades
Insider Sales IMDX / Insight Molecular Diagnostics Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in IMDX / Insight Molecular Diagnostics Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IMDX / Insight Molecular Diagnostics Inc. Insider Trades
Insider Purchases LCTX / Lineage Cell Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in IMDX / Insight Molecular Diagnostics Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2017-08-22 BTX WEST MICHAEL D 2,000 2.5990 2,000 2.5990 5,198 0 2.4431 -312 -6.00
2012-05-31 BTX WEST MICHAEL D 10,000 4.0490 10,000 4.0490 40,490

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

LCTX / Lineage Cell Therapeutics, Inc. Insider Trades
Insider Sales LCTX / Lineage Cell Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in IMDX / Insight Molecular Diagnostics Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2014-07-22 BTX WEST MICHAEL D 270,000 2.6500 270,000 2.6500 715,500 266 4.9754 627,858 87.75

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

LCTX / Lineage Cell Therapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Michael D West as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2023-03-14 2023-03-11 4 AGE AgeX Therapeutics, Inc.
Common Stock, $0.0001 par value
F - Taxes -1,060 41,982 -2.46 0.59 -625 24,769
2023-03-14 2023-03-11 4 AGE AgeX Therapeutics, Inc.
Common Stock, $0.0001 par value
M - Exercise 3,125 43,042 7.83
2022-12-13 2022-12-11 4 AGE AgeX Therapeutics, Inc.
Common Stock, $0.0001 par value
F - Taxes -1,081 39,917 -2.64 0.59 -638 23,551
2022-12-13 2022-12-11 4 AGE AgeX Therapeutics, Inc.
Common Stock, $0.0001 par value
M - Exercise 3,125 40,998 8.25
2022-09-13 2022-09-11 4 AGE AgeX Therapeutics, Inc.
Common Stock, $0.0001 par value
F - Taxes -1,081 44,503 -2.37 0.56 -608 25,024
2022-09-13 2022-09-11 4 AGE AgeX Therapeutics, Inc.
Common Stock, $0.0001 par value
M - Exercise 3,125 45,584 7.36
2022-06-14 2022-06-11 4 AGE AgeX Therapeutics, Inc.
Common Stock, $0.0001 par value
F - Taxes -1,081 42,459 -2.48 0.77 -833 32,702
2022-06-14 2022-06-11 4 AGE AgeX Therapeutics, Inc.
Common Stock, $0.0001 par value
M - Exercise 3,125 43,540 7.73
2022-03-15 2022-03-11 4 AGE AgeX Therapeutics, Inc.
Restricted Stock Units
M - Exercise -3,125 12,500 -20.00
2022-03-15 2022-03-11 4 AGE AgeX Therapeutics, Inc.
Common Stock, $0.0001 par value
F - Taxes -1,281 40,415 -3.07 0.69 -887 27,979
2022-03-15 2022-03-11 4 AGE AgeX Therapeutics, Inc.
Common Stock, $0.0001 par value
M - Exercise 3,125 41,696 8.10
2021-12-14 2021-12-11 4 AGE AgeX Therapeutics, Inc.
Restricted Stock Units
M - Exercise -3,125 15,625 -16.67
2021-12-14 2021-12-11 4 AGE AgeX Therapeutics, Inc.
Common Stock, $0.0001 par value
F - Taxes -1,081 38,571 -2.73 0.64 -686 24,493
2021-12-14 2021-12-11 4 AGE AgeX Therapeutics, Inc.
Common Stock, $0.0001 par value
M - Exercise 3,125 39,652 8.56
2021-09-21 2021-09-11 4 AGE AgeX Therapeutics, Inc.
Restricted Stock Units
M - Exercise -3,125 18,750 -14.29
2021-09-21 2021-09-11 4 AGE AgeX Therapeutics, Inc.
Common Stock, $0.0001 par value
F - Taxes -1,081 36,527 -2.87 1.00 -1,078 36,436
2021-09-21 2021-09-11 4 AGE AgeX Therapeutics, Inc.
Common Stock, $0.0001 par value
M - Exercise 3,125 37,608 9.06
2021-06-15 2021-06-11 4 AGE AgeX Therapeutics, Inc.
Restricted Stock Units
M - Exercise -3,125 21,875 -12.50
2021-06-15 2021-06-11 4 AGE AgeX Therapeutics, Inc.
Common Stock, $0.0001 par value
F - Taxes -1,081 34,483 -3.04 1.53 -1,654 52,759
2021-06-15 2021-06-11 4 AGE AgeX Therapeutics, Inc.
Common Stock, $0.0001 par value
M - Exercise 3,125 35,564 9.63
2021-06-08 2021-06-04 4 AGE AgeX Therapeutics, Inc.
Option to Purchase Common Stock
A - Award 120,000 120,000
2021-03-15 2021-03-11 4 AGE AgeX Therapeutics, Inc.
Restricted Stock Units
M - Exercise -3,125 25,000 -11.11
2021-03-15 2021-03-11 4 AGE AgeX Therapeutics, Inc.
Common Stock, $0.0001 par value
F - Taxes -1,284 32,439 -3.81 2.03 -2,607 65,851
2021-03-15 2021-03-11 4 AGE AgeX Therapeutics, Inc.
Common Stock, $0.0001 par value
M - Exercise 3,125 33,723 10.21
2020-12-15 2020-12-11 4 AGE AgeX Therapeutics, Inc.
Restricted Stock Units
M - Exercise -3,125 28,125 -10.00
2020-12-15 2020-12-11 4 AGE AgeX Therapeutics, Inc.
Common Stock, $0.0001 par value
F - Taxes -1,081 30,598 -3.41 1.69 -1,827 51,711
2020-12-15 2020-12-11 4 AGE AgeX Therapeutics, Inc.
Common Stock, $0.0001 par value
M - Exercise 3,125 31,679 10.94
2020-09-15 2020-09-11 4 AGE AgeX Therapeutics, Inc.
Restricted Stock Units
M - Exercise -3,125 31,250 -9.09
2020-09-15 2020-09-11 4 AGE AgeX Therapeutics, Inc.
Common Stock, $0.0001 par value
F - Taxes -1,081 28,554 -3.65 0.81 -875 23,114
2020-09-15 2020-09-11 4 AGE AgeX Therapeutics, Inc.
Common Stock, $0.0001 par value
M - Exercise 3,125 29,635 11.79
2020-06-15 2020-06-11 4 AGE AgeX Therapeutics, Inc.
Restricted Stock Units
M - Exercise -3,125 34,375 -8.33
2020-06-15 2020-06-11 4 AGE AgeX Therapeutics, Inc.
Common Stock, $0.0001 par value
F - Taxes -1,081 26,510 -3.92 0.80 -865 21,211
2020-06-15 2020-06-11 4 AGE AgeX Therapeutics, Inc.
Common Stock, $0.0001 par value
M - Exercise 3,125 27,591 12.77
2020-03-13 2020-03-11 4 AGE AgeX Therapeutics, Inc.
Restricted Stock Units
M - Exercise -12,500 37,500 -25.00
2020-03-13 2020-03-11 4 AGE AgeX Therapeutics, Inc.
Common Stock, $0.0001 par value
F - Taxes -5,085 24,446 -17.22 0.88 -4,463 21,456
2020-03-13 2020-03-11 4 AGE AgeX Therapeutics, Inc.
Common Stock, $0.0001 par value
M - Exercise 12,500 29,551 73.31
2019-03-13 2019-03-11 4 AGE AgeX Therapeutics, Inc.
Restricted Stock Units
A - Award 50,000 50,000
2019-03-13 2019-03-11 4 AGE AgeX Therapeutics, Inc.
Option to Purchase Common Stock
A - Award 100,000 100,000
2018-12-12 2018-12-10 4 AGE AgeX Therapeutics, Inc.
Common Stock, $0.0001 par value
P - Purchase 4,000 15,460 34.90 3.86 15,443 59,686
2018-09-19 2018-09-17 4 BTX BIOTIME INC
Restricted Stock Units
M - Exercise -10,938 0 -100.00
2018-09-19 2018-09-17 4 BTX BIOTIME INC
Common Shares, no par value
F - Taxes -3,783 893,913 -0.42 2.31 -8,739 2,064,939
2018-09-19 2018-09-17 4 BTX BIOTIME INC
Common Shares, no par value
M - Exercise 10,938 897,696 1.23
2018-07-12 2018-07-10 4 BTX BIOTIME INC
Restricted Stock Units
M - Exercise -1,562 10,938 -12.50
2018-07-12 2018-07-10 4 BTX BIOTIME INC
Common Shares, no par value
F - Taxes -541 886,758 -0.06 2.20 -1,190 1,950,868
2018-07-12 2018-07-10 4 BTX BIOTIME INC
Common Shares, no par value
M - Exercise 1,562 887,299 0.18
2018-04-12 2018-04-10 4 BTX BIOTIME INC
Restricted Stock Units
M - Exercise -1,563 12,500 -11.11
2018-04-12 2018-04-10 4 BTX BIOTIME INC
Common Shares, no par value
F - Taxes -541 885,737 -0.06 2.49 -1,347 2,205,485
2018-04-12 2018-04-10 4 BTX BIOTIME INC
Common Shares, no par value
M - Exercise 1,563 886,278 0.18
2018-01-12 2018-01-10 4 BTX BIOTIME INC
Restricted Stock Units
M - Exercise -1,562 14,063 -10.00
2018-01-12 2018-01-10 4 BTX BIOTIME INC
Common Shares, no par value
F - Taxes -686 884,715 -0.08 2.68 -1,838 2,371,036
2018-01-12 2018-01-10 4 BTX BIOTIME INC
Common Shares, no par value
M - Exercise 1,562 885,401 0.18
2017-10-12 2017-10-10 4 BTX BIOTIME INC
Restricted Stock Units
M - Exercise -1,563 15,625 -9.09
2017-10-12 2017-10-10 4 BTX BIOTIME INC
Common Shares, no par value
F - Taxes -588 883,839 -0.07 2.81 -1,652 2,483,588
2017-10-12 2017-10-10 4 BTX BIOTIME INC
Common Shares, no par value
M - Exercise 1,563 884,427 0.18
2017-08-23 2017-08-22 4 BTX BIOTIME INC
Common Shares, no par value
P - Purchase 2,000 882,864 0.23 2.60 5,198 2,294,564
2017-07-12 2017-07-10 4 BTX BIOTIME INC
Restricted Stock Units
M - Exercise -1,562 17,188 -8.33
2017-07-12 2017-07-10 4 BTX BIOTIME INC
Common Shares, no par value
F - Taxes -587 880,864 -0.07 3.09 -1,814 2,721,870
2017-07-12 2017-07-10 4 BTX BIOTIME INC
Common Shares, no par value
M - Exercise 1,562 881,451 0.18
2017-05-01 2017-04-10 4 BTX BIOTIME INC
Restricted Stock Units
M - Exercise -6,250 18,750 -25.00
2017-05-01 2017-04-10 4 BTX BIOTIME INC
Common Shares, no par value
F - Taxes -2,348 879,889 -0.27 3.33 -7,819 2,930,030
2017-05-01 2017-04-10 4 BTX BIOTIME INC
Common Shares, no par value
M - Exercise 6,250 882,237 0.71
2016-04-11 2016-04-07 4 BTX BIOTIME INC
Restricted Stock Units
A - Award 25,000 25,000
2016-04-11 2016-04-07 4 BTX BIOTIME INC
Option to Purchase Common Shares
A - Award 175,000 175,000
2016-02-18 2016-02-16 4 OCX OncoCyte Corp
Option to Purchase Common Stock
A - Award 60,000 60,000
2016-01-04 3 OCX OncoCyte Corp
Common Stock, no par value
87,598
2016-01-04 3 OCX OncoCyte Corp
Common Stock, no par value
87,598
2015-07-14 2015-07-10 4 BTX BIOTIME INC
Option to Purchase Common Shares
A - Award 200,000 200,000
2015-02-18 2015-02-13 4 AST Asterias Biotherapeutics, Inc.
Restricted Stock Units
A - Award 3,846 3,846
2015-02-18 2015-02-13 4 AST Asterias Biotherapeutics, Inc.
Stock Option (right to buy)
A - Award 20,000 20,000
2014-07-23 2014-07-22 4 BTX BIOTIME INC
Common Shares, no par value
S - Sale -270,000 875,987 -23.56 2.65 -715,500 2,321,366
2014-07-23 2014-07-21 4 BTX BIOTIME INC
Option to Purchase Common Shares
M - Exercise -1,470,400 0 -100.00
2014-07-23 2014-07-21 4 BTX BIOTIME INC
Common Shares, no par value
F - Taxes -434,013 1,145,987 -27.47 2.65 -1,150,134 3,036,866
2014-07-23 2014-07-21 4 BTX BIOTIME INC
Common Shares, no par value
M - Exercise 1,470,400 1,580,000 1,341.61 0.50 735,200 790,000
2014-03-24 2014-03-20 4 BTX BIOTIME INC
Option to Purchase Common Shares
J - Other 200,000 200,000
2013-02-22 2013-02-20 4 BTX BIOTIME INC
Option to Purchase Common Shares
J - Other 200,000 200,000
2012-05-31 2012-05-31 4 BTX BIOTIME INC
Common Shares, no par value
P - Purchase 10,000 109,600 10.04 4.05 40,490 443,770
2012-04-26 2012-04-24 4 BTX BIOTIME INC
Option to Purchase Common Shares
M - Exercise -20,000 0 -100.00
2012-04-26 2012-04-24 4 BTX BIOTIME INC
Common Shares, no par value
M - Exercise 20,000 99,600 25.13 0.74 14,800 73,704
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)